Apollon Formularies set for US listing on OTCQB

Apollon Formularies PLC (AQSE:APOL) told investors that it is advancing an application to join the OTCQB Market in the United States.

The cannabis company, in a statement, said has decided to apply for the second listing in at the request of several US based investors.

It added that cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity.

"With Apollon's primary operations based in Jamaica, having a platform in the USA is an important step in our growth strategy,” said chief executive Dr Stephen Barnhill.

“Onboarding onto the OTCQB will strengthen Apollon's visibility and transparency within the US public market and will provide access to a new international investor base.

He added: "Alongside the OTCQB trading, Apollon is also exploring an up-listing to another larger more liquid exchange. Whilst we cannot provide any further detail at this stage, we will continue to explore these opportunities to drive shareholder value."

Apollon said it believes a move to a more well-established exchange will provide easier trading access for institutional investors and improve liquidity for all shareholders.

< Back to News